HIGHLIGHTS
- who: from the (UNIVERSITY) have published the paper: The Journal of Clinical Investigation, in the Journal: (JOURNAL)
- what: The study demonstrates that some hyperimmune COVIDIVIG lots manufactured in 2020 (2020-hCoV-2IG) neutralized several Omicron variants, similar to CP, from Omicron breakthrough infections in individuals with prior vaccination (2022-CP), at a level (PsVNA50 titer of >1:40) predicted to provide protection against severe COVID-19 .
SUMMARY
In contrast, weak insignificant correlations were observed between PsVNA50 titers against WA-1/2020 and BQ.1, BQ.1.1, and XBB. The study . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.